Journal
MEDICINAL RESEARCH REVIEWS
Volume 41, Issue 3, Pages 1499-1538Publisher
WILEY
DOI: 10.1002/med.21766
Keywords
metabolism; prostate cancer; therapy
Categories
Funding
- FEDER funds through the POCI-COMPETE 2020 [007491, 029114]
- Foundation for Science and Technology [SFRH/BD/104671/2014, SFRH/BD/111351/2015, UID/Multi/00709/2019]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/111351/2015, UID/Multi/00709/2019, SFRH/BD/104671/2014] Funding Source: FCT
Ask authors/readers for more resources
Prostate cancer metabolism is becoming increasingly important, with metabolic reprogramming and activation of specific pathways playing a crucial role in therapy. Glucose, lipids, and glutamine are essential for PCa cell survival and growth.
Prostate cancer (PCa), one of the most commonly diagnosed cancers worldwide, still presents important unmet clinical needs concerning treatment. In the last years, the metabolic reprogramming and the specificities of tumor cells emerged as an exciting field for cancer therapy. The unique features of PCa cells metabolism, and the activation of specific metabolic pathways, propelled the use of metabolic inhibitors for treatment. The present work revises the knowledge of PCa metabolism and the metabolic alterations that underlie the development and progression of the disease. A focus is given to the role of bioenergetic sources, namely, glucose, lipids, and glutamine sustaining PCa cell survival and growth. Moreover, it is described as the action of oncogenes/tumor suppressors and sex steroid hormones in the metabolic reprogramming of PCa. Finally, the status of PCa treatment based on the inhibition of metabolic pathways is presented. Globally, this review updates the landscape of PCa metabolism, highlighting the critical metabolic alterations that could have a clinical and therapeutic interest.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available